ipragliflozin: Clinical Trials

19 trials of ipragliflozin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed, 1 terminated. 19 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 319Completed 18, Terminated 1

Follow ipragliflozin: new trials by email Literature Review of ipragliflozin trials Research Report on ipragliflozin

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin
Ipragliflozin, Sitagliptin - Type 2 Diabetes Mellitus
Phase 3CompletedSeoul National University Bundang Hospital1702017-04-252022-10-04
A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus
ipragliflozin, Placebo, Insulin Therapy - Type 1 Diabetes Mellitus
Phase 3CompletedAstellas Pharma Inc1752016-08-292024-11-12
A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin
Ipragliflozin L-proline, Metformin, Placebo - Type 2 Diabetes Mellitus
Phase 3CompletedAstellas Pharma Europe B.V.2682016-05-112024-11-12
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
Ipragliflozin, Placebo, Sitagliptin - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC1432015-11-092018-09-04
Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)
Sitagliptin, Placebo, Ipragliflozin - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC1412015-11-052018-08-31
Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
Ipragliflozin, Sitagliptin - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC772015-10-262018-09-04
A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin
ASP1941, Placebo - Type 2 Diabetes Mellitus
Phase 3CompletedAstellas Pharma Korea, Inc.1432015-06-222024-11-12
A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients
ipragliflozin - Type 2 Diabetes Mellitus
Phase 3CompletedAstellas Pharma Inc1742012-05-252024-11-08
A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus
ASP1941, acarbose, Placebo - Type II Diabetes Mellitus
Phase 3TerminatedAstellas Pharma Inc462012-04-232024-11-12
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients
ASP1941, metformin, Placebo - Type II Diabetes Mellitus
Phase 3CompletedAstellas Pharma Inc1712011-11-282024-11-12
A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment
ASP1941, placebo - Type 2 Diabetes Mellitus
Phase 3CompletedAstellas Pharma Inc1652011-01-182025-05-22
A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients
ipragliflozin, nateglinide - Type 2 Diabetes Mellitus
Phase 3CompletedAstellas Pharma Inc1222011-01-152025-05-30
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients
ipragliflozin, alpha glucosidase inhibitor - Type 2 Diabetes Mellitus
Phase 3CompletedAstellas Pharma Inc1132010-10-212025-05-30
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients
ipragliflozin, DPP-4 inhibitor - Type 2 Diabetes Mellitus
Phase 3CompletedAstellas Pharma Inc1062010-10-212025-05-30
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients
ipragliflozin, Placebo, Sulfonylurea - Type 2 Diabetes Mellitus
Phase 3CompletedAstellas Pharma Inc2432010-09-172025-05-30
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients
ipragliflozin, Placebo, Pioglitazone - Type 2 Diabetes Mellitus
Phase 3CompletedAstellas Pharma Inc1522010-09-152025-05-30
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients
ipragliflozin, Placebo, metformin - Type 2 Diabetes Mellitus
Phase 3CompletedAstellas Pharma Inc1682010-05-152025-05-30
A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients
ipragliflozin - Type 2 Diabetes Mellitus
Phase 3CompletedAstellas Pharma Inc1822010-01-142025-05-30
A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients
ipragliflozin, placebo - Type 2 Diabetes Mellitus
Phase 3CompletedAstellas Pharma Inc1302010-01-132025-05-30

Conditions studied

Diabetes Mellitus, Type 2 (18)  ·  Diabetes Mellitus (9)  ·  Glycosuria (2)  ·  Diabetes Mellitus, Type 1 (1)  ·  Renal Insufficiency (1)

Sponsors

Astellas Pharma Inc (13)  ·  Merck Sharp & Dohme LLC (3)  ·  Astellas Pharma Europe B.V. (1)  ·  Astellas Pharma Korea, Inc. (1)  ·  Seoul National University Bundang Hospital (1)

Countries

Japan (11)  ·  South Korea (4)  ·  Taiwan (2)  ·  Russia (1)

Top investigators

Soo Lim (1)

Results publications

PMID 31606880, PMID 34033212, PMID 33565686, PMID 38770818